![【高血壓英文課件】-Getting-Blood-Pressure-to-Goal_第1頁](http://file4.renrendoc.com/view/5153efda096060bfa9c88ab8a1e901b0/5153efda096060bfa9c88ab8a1e901b01.gif)
![【高血壓英文課件】-Getting-Blood-Pressure-to-Goal_第2頁](http://file4.renrendoc.com/view/5153efda096060bfa9c88ab8a1e901b0/5153efda096060bfa9c88ab8a1e901b02.gif)
![【高血壓英文課件】-Getting-Blood-Pressure-to-Goal_第3頁](http://file4.renrendoc.com/view/5153efda096060bfa9c88ab8a1e901b0/5153efda096060bfa9c88ab8a1e901b03.gif)
![【高血壓英文課件】-Getting-Blood-Pressure-to-Goal_第4頁](http://file4.renrendoc.com/view/5153efda096060bfa9c88ab8a1e901b0/5153efda096060bfa9c88ab8a1e901b04.gif)
![【高血壓英文課件】-Getting-Blood-Pressure-to-Goal_第5頁](http://file4.renrendoc.com/view/5153efda096060bfa9c88ab8a1e901b0/5153efda096060bfa9c88ab8a1e901b05.gif)
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
GettingBloodPressuretoGoalRulesofThree:3drugs3months3behaviors(Activity-Diet-ControlofTobaccoandAlcohol)3Partners(Patient–Family–Provider)GettingBloodPressuretoGoal1ThisprogramwassponsoredbytheNationalKidneyFoundationofMichigan(NKFM)andtheMichiganDepartmentofCommunityHealth(MDCH).FundingwasprovidedbyagenerousgrantfromNKFMandMDCHandvariouspharmacompanies.ContinuingMedicalEducationcreditisprovidedbyWayneStateUniversitySchoolofMedicineTheprogramwasdevelopedandpreparedby:
DianeLevine,MDWayneStateUniversitySilasNorman,MD,UniversityofMichiganRosalindPeters,PhD,RN,WayneStateUniversitySusanSteigerwalt,MD,St.JohnHospitalWithinputfromtheHypertensionExpertGroupofNKFMandtheexpertiseandcreativityofitsmemberswithspecialthankstoVelmaTheisenandLindaSmithWheelockACSW,MSBAThisprogramwassponsoredby2ConflictofInterestIndividualSpeakerstoAddtheirinformationpriortopresenting
ConflictofInterestIndividual3【高血壓英文課件】-Getting-Blood-Pressure-to-Goal4【高血壓英文課件】-Getting-Blood-Pressure-to-Goal5MajorityofUSHypertensivePatientsNotatSBPGoalof<140mmHgMajorityofUSHypertensivePa6UnacceptableBPControlRatesRequireIncreasedAwareness,MoreAggressiveTreatmentUnacceptableBPControlRates7SignificanceofHBPProblem50%ofhypertensivesareuncontrolled.UptohalfarenotreceivingpharmacologictreatmentAntihypertensivetherapycanStroke–30%CHF–40-50%CAD–10-20%CADEvents-~55%Mortality–10%~$1Billionindirectmedicalcosts/yearSignificanceofHBPProblem50%8CardiovascularMortalityRiskDoublesWithEach20/10mmHgBPIncrement*CardiovascularMortalityRisk9CV-RelatedMortalityRatesAreHigherinAfricanAmericansCV-RelatedMortalityRatesAre10CardiovascularEventsinTreatedHypertensiveDiabeticPatientsCardiovascularEventsinTreat11PreventingKidneyFailureAfricanAmericansinMichiganhavepoorerbloodpressurecontrolthanCaucasiansAfricanAmericansareatfivetimesgreaterriskofprogressiontoendstagerenaldiseaseBetterbloodpressurecontrolSLOWSPROGRESSIONofrenaldiseaseBPcontrolreducestheriskofstroke,MI,andCHFPreventingKidneyFailureAfric12FactorsContributingtoPoorBPControlPatientFactorsAgeRace/ethnicityObesityAccessNonadherenceKnowledgeCostComplextreatmentPt/ProviderCommunicationSecondaryHTNProviderFactorsMeasurementissuesLackofknowledge/DisagreementwithguidelinesConcernforsideeffectsNon-advancingofdrugsinasymptomaticpatientsResponsetopatientsconcernsovercomplexityoftreatmentLackoftimeFactorsContributingtoPoorB13MeasurementAccuracyAccuracyofofficemeasurementsManual–RegularlycalibratedWhite-CoatSyndromeHomeMonitoring
OmronHealthcareArm(notwrist)monitorGoalreadings<135/85MeasurementAccuracyAccuracyo14
MeasurementAccuracy*
PatientPosition:BacksupportedFeetonthefloorArmattheleveloftheheartNotalkingCuffSize–Mostadultsneedalargecuff(SeeCDandAHAwebsitefordetails)TaketwiceCheckorthostaticbloodpressure*CDprovidedtosupportreviewandstandardizationofBPmeasurement
MeasurementAccuracy*
Pa15MeasurementAccuracy:
OrthostaticHypotension20%prevalenceincommunitydwellingadultsoverage65IncreaseswithagePresentinyoungerpatientswithdiabetesorautonomicdysfunction“Iforthostasiscannotbecorrected,usestandingBPtoassessgoalBP”(JNC-7)MeasurementAccuracy:
Orthosta16JNC7:NewBPClassificationsJNC7:NewBPClassifications17JNC7RecommendedBPGoals<140and<90mmHg
Patientswithmostconditions<130and<80mmHgDiabetesMellitusCKDAlbuminuria>300mg/24hror>200mg/gurinarycreatinineeGFR<60ml/min/1.73m2SerumcreatininelevelsaloneoverestimatekidneyfunctionAssessandaddressothercardiovascularriskfactorsChobanianAVetal.JAMA.2003;289:2560-2572.JNC7RecommendedBPGoals<14018JNC7:ManagementofHypertensionbyBPClassificationJNC7:ManagementofHypertens19CommonProviderConcernswithGuidelineGoals
NonAcceptanceofBPgoalsResistancetoacceptSBPthresholdsNottreatingunlessSBP>160mmHgConcernsofincreasedcardiovascularriskwithexcessiveloweringofDBP(J-Curve)BelievethatmoretimeisneededtoreachgoalVALUE,
LANCET,2004:363:2022-2031CommonProviderConcernswith20Ruleof3
“MDBP”3
Months3
Drugs3
Behaviors
(activity-diet-alcoholandtobaccocontrol)3
Partners
(Patient–Family–Provider)Ruleof3
“MDBP”3Months21
ItMightTake3MonthsGettingBPtogoalin3monthsRequiresmultiplevisitsGettingtoGoalvisitschedule:MonthlyuntilgoalisreachedIncreasevisitfrequencyifStage2Increasevisitfrequencywithcomorbidconditions
Atgoal–followupvisitscheduleEvery3-6monthsdependingoncomorbiditiesCheckK+andCreatinine1-2x/year
ItMightTake3MonthsGetting22
DrugTherapyStepApproach:StartwithdiureticifnocontraindicationsAddACEICalciumChannelBlocker(CCB)Betablockers–butcautionMostpatientsrequire
multipledrugstoachievecontrol(average=3.5drugs)Usemultipledrugsif:BP20/10mmHgabovegoal(Stage22drugs)StandingBPabovegoalinpatientsoverage65orDMNotatgoalafter3months
DrugTherapyStepApproach:23MultipleAntihypertensiveAgentsAreNeededtoAchieveTargetBloodPressureMultipleAntihypertensiveAgen24DrugTreatment:DiureticsIfnocompellingindications(CHF,diabetes,CKD)Chlorthalidone(orotherthiazides)firstThenACEIorARBRememberBetaBlockersARENOTforprimarypreventionandareinferiortodiureticsasmonotherapyVigilantlypreventhypokalemiaSpironolactone/HCTZisagreatcombination!BringpatientsbackinoneweektocheckfordiureticinducedhypokalemiaWatchforhyponatremiaDrugTreatment:DiureticsIfno25DrugTreatment:ACEinhibitorsCheckElectrolytes,BUN,andCreatininepriortostartingRecheckK+andCreatinine1weekafterinitiationoftherapyGenericavailableBIDDosing:enalapril(5mgbid-20mgbid)captopril(12.5mgbid-50mgbid)DailyDosinglisinopril(5-40mgdaily)Sideeffects:Cough-switchtoARBifaffordableHyperkalemiaandacuterenalfailureAngioedemaDrugTreatment:ACEinhibitors26WhatHaveWeLearned?
TreatmentTreatmentoftheveryelderlydecreases strokeandCADbutdoesnotprolongsurvival(Lancet1999:353:793)Bestdrugsinrankorder:ChlorthalidoneACEinhibitorHCTZ(Hypertension2004;44:800)CCB
WhatHaveWeLearned?
Treatme27WhatHaveWeLearned?
TreatmentACEIandARBdecreasenewonsetofdiabetesby25%comparedtobetablockers(LIFE);23%comparedtoCCBs(VALUEtrial)NewonsetofdiabeteswhileundergoingtreatmentforhypertensionconfersthesameexcessCVriskaspreexistingdiabetes(Hypertension(2004)43p.963)WhatHaveWeLearned?
Treatme28WhatHaveWeLearned?
TreatmentMonotherapywithatenololisNOTasefficaciousasotherantihypertensivesfordecreasingCVriskdespiteequivalentBPcontrol(Lancet:2004:364:1684)BetablockersareinferiortodiureticsforbloodpressurecontrolandCVriskprotection(stroke,CHF)inolderpatients(MRCtrial,1990;JAMA
1998;279:1903-1907;INVEST:JAMA290:2805-2816;ASCOTTrial)WhatHaveWeLearned?
Treatme29CombinationTreatmentsLogical/additivecombinationsDiuretic+ACEIorARBDiuretic+BetaBlockerorsympatholyticsCCB+ACEIorARBDiuretic+BetaBlocker+vasodilatorDiuretic+CCBCombinationTreatmentsLogical30CombinationTreatmentsCombinationswithNOadditiveeffectBetaBlocker+ACEIVasodilators+CCBCombinationwithadditivesideeffectsBetaBlocker+clonidineorguanfacineBetaBlocker+verapamilordiltiazemClonidine/guanfacine+verapamilordiltiazemCombinationTreatmentsCombinat31Whenadding
Indifficulttocontrolpatients
ItTakes3DRUGS!ChoosealogicalADDITIVEcombinations:Diuretic+ACEI+CCBDiuretic+BBlocker+vasodilatorDiuretic+clonidine+vasodilatorWhenadding
32SpecialPopulationsDiabetesACEIorARBDiureticsareimportantadjuncttherapyBScontrolassociatedwithBPcontrolCKDACEIorARBareimportanttopreserverenalfunctionIfeGFR<50starttorsemideorfurosemidebidPostMIBetablockersACEIorARBCheckK+andCreatininepriortoinitiatingand1weekafterinitiatingACESpecialPopulationsDiabetes33
ItMightTake3MonthsButifnotatgoalby6monthsconsider:PatientreasonsfornonadherenceSleepApneaAlcoholoveruseDiabetesChronicKidneyDiseaseSecondarycausesConsultwithorrefertoHypertensionSpecialist
VALUE,LANCET,2004:363:2022-2031
ItMightTake3MonthsButif34SleepApneaUpto60%maleswithresistanthypertension(alsocommoninpostmenopausalfemales)Suspectdiagnosis-screenandreferPathophysiologyofhypertensionlikelySNSactivationSleepApneaUpto60%maleswit35
Lifestyle:ItTakes3BEHAVIORSExerciseDietControloftobaccoandalcohol
Lifestyle:ItTakes3BEHAVIO36Lifestyle:Exercise4-9mmHgSBPreduction30-45minutes/day/5-7days/weekAerobicactivity(e.g.briskwalking)WriteaprescriptionFavoritePatientSig40minutesofwalking5X/wk BPMD3333Lifestyle:Exercise4-9mmHgSBP37Lifestyle:DietWeightControl
5-20mmHgSBPreduction/10kgLowSodium(<2.4g)
2-8mmHgSBPreductionDASH8-14mmHgSBPreductionLifestyle:DietWeightControl38ControlofTobaccoandAlcoholSmokingCessationWriteprescriptionAlcoholModeration<2alcoholicdrinks/day–men<1alcoholicdrink/day–women2-4mmHgreductioninSBPAccessforothersubstancesControlofTobaccoandAlcohol39Partners:Ittakes3PartnersPatientFamilyProviderProvider/PatientRelationshipKeyPartners:Ittakes3PartnersP40ThePatient:Participationiscrucial
Describethejourney“Thisisaseriousdisease”“Iwillneedtoseeyouevery4-6weeks”“Thisisyourgoal<140/90(or130/80)”“Achievingyourgoalisimportantbecauseitlowersyourriskof…Sharegoalsetting“Let’ssetsomegoals“Thishowcanyouhelp“Whatareyouwillingtodo?“Weareateam—Patient,provider,“family”Ifwedonotachieveyourgoals…ThePatient:Participationis41Partners:PatientsPatientnon-adherencetotherapyLackofconcernifasymptomaticFeel“better”withhigherBPDon’tworryabout“touch”ofhighBPMistrustofhealthcareprovidersandhealthcaresystemImprovedadherencewithIncreasedcontactwithprovidersSelf/homeBPmeasurement-OMRONarm,usuallyLARGEADULTcuff(Bladderencircling80%arm)Useofpatientrecordtokeeptrackofinfluenceoffactors(e.g.diet)onBPPartners:PatientsPatientnon-42Partners:
“Family”,Friends,CommunityInvolve“family”wheneverpossibleEssentialforlifestylemodificationBefamiliarwithcommunityresourcesPartners:
“Family”,Friends,43Partners:ProvidersFollowJNCandMQIC*GuidelinesDocumentGoalSchedulefrequentvisitstogettogoal
3monthstogoal!!!!ToolstogettogoaleGFRslideruletoassessrenalfunctionCollaborativepracticewithAPNsimprovescontrol*www.MQIC.orgPartners:ProvidersFollowJNC44ProviderStepsto
IncreaseAdherenceWritelifestyleprescriptionsConsidercostsofdrugs–genericswheneverpossibleSimplifydrugregimensDailytherapyorBIDAddresspatient’sunderstandingofthediseaseanditstreatmentTelephonefollowupsincreaseadherenceespeciallyfor“noshows”trytokeepthemintreatmentAdditionalfollowupasnegotiatedwithpatientOfficeRNorAPNwillincreaseBPcontrol(CollaborativePractice)ProviderStepsto
IncreaseAd45KeyPointsfromPresentation
MeasurementAccuracyisimportantDetermineGoalBP<140/90<130/80DMCKDFollowguidelinesRulesof3(MDBP)3
Months3
Drugs3
Behaviors3
PartnersKeyPointsfromPresentationM46HandoutsInformationcontainedonCDTonight’sslidepresentation–sharewithcolleaguesBPmeasurementprotocolMQICguidelinesNHLBIDASHdietinformationPatientHealthRecordPrescriptionpadsforexercise/lifestyleprescriptionsHandoutsInformationcontained47Questions?
Casesyou’dliketodiscuss?Questions?
Casesyou’dliket48GettingBloodPressuretoGoalRulesofThree:3drugs3months3behaviors(Activity-Diet-ControlofTobaccoandAlcohol)3Partners(Patient–Family–Provider)GettingBloodPressuretoGoal49ThisprogramwassponsoredbytheNationalKidneyFoundationofMichigan(NKFM)andtheMichiganDepartmentofCommunityHealth(MDCH).FundingwasprovidedbyagenerousgrantfromNKFMandMDCHandvariouspharmacompanies.ContinuingMedicalEducationcreditisprovidedbyWayneStateUniversitySchoolofMedicineTheprogramwasdevelopedandpreparedby:
DianeLevine,MDWayneStateUniversitySilasNorman,MD,UniversityofMichiganRosalindPeters,PhD,RN,WayneStateUniversitySusanSteigerwalt,MD,St.JohnHospitalWithinputfromtheHypertensionExpertGroupofNKFMandtheexpertiseandcreativityofitsmemberswithspecialthankstoVelmaTheisenandLindaSmithWheelockACSW,MSBAThisprogramwassponsoredby50ConflictofInterestIndividualSpeakerstoAddtheirinformationpriortopresenting
ConflictofInterestIndividual51【高血壓英文課件】-Getting-Blood-Pressure-to-Goal52【高血壓英文課件】-Getting-Blood-Pressure-to-Goal53MajorityofUSHypertensivePatientsNotatSBPGoalof<140mmHgMajorityofUSHypertensivePa54UnacceptableBPControlRatesRequireIncreasedAwareness,MoreAggressiveTreatmentUnacceptableBPControlRates55SignificanceofHBPProblem50%ofhypertensivesareuncontrolled.UptohalfarenotreceivingpharmacologictreatmentAntihypertensivetherapycanStroke–30%CHF–40-50%CAD–10-20%CADEvents-~55%Mortality–10%~$1Billionindirectmedicalcosts/yearSignificanceofHBPProblem50%56CardiovascularMortalityRiskDoublesWithEach20/10mmHgBPIncrement*CardiovascularMortalityRisk57CV-RelatedMortalityRatesAreHigherinAfricanAmericansCV-RelatedMortalityRatesAre58CardiovascularEventsinTreatedHypertensiveDiabeticPatientsCardiovascularEventsinTreat59PreventingKidneyFailureAfricanAmericansinMichiganhavepoorerbloodpressurecontrolthanCaucasiansAfricanAmericansareatfivetimesgreaterriskofprogressiontoendstagerenaldiseaseBetterbloodpressurecontrolSLOWSPROGRESSIONofrenaldiseaseBPcontrolreducestheriskofstroke,MI,andCHFPreventingKidneyFailureAfric60FactorsContributingtoPoorBPControlPatientFactorsAgeRace/ethnicityObesityAccessNonadherenceKnowledgeCostComplextreatmentPt/ProviderCommunicationSecondaryHTNProviderFactorsMeasurementissuesLackofknowledge/DisagreementwithguidelinesConcernforsideeffectsNon-advancingofdrugsinasymptomaticpatientsResponsetopatientsconcernsovercomplexityoftreatmentLackoftimeFactorsContributingtoPoorB61MeasurementAccuracyAccuracyofofficemeasurementsManual–RegularlycalibratedWhite-CoatSyndromeHomeMonitoring
OmronHealthcareArm(notwrist)monitorGoalreadings<135/85MeasurementAccuracyAccuracyo62
MeasurementAccuracy*
PatientPosition:BacksupportedFeetonthefloorArmattheleveloftheheartNotalkingCuffSize–Mostadultsneedalargecuff(SeeCDandAHAwebsitefordetails)TaketwiceCheckorthostaticbloodpressure*CDprovidedtosupportreviewandstandardizationofBPmeasurement
MeasurementAccuracy*
Pa63MeasurementAccuracy:
OrthostaticHypotension20%prevalenceincommunitydwellingadultsoverage65IncreaseswithagePresentinyoungerpatientswithdiabetesorautonomicdysfunction“Iforthostasiscannotbecorrected,usestandingBPtoassessgoalBP”(JNC-7)MeasurementAccuracy:
Orthosta64JNC7:NewBPClassificationsJNC7:NewBPClassifications65JNC7RecommendedBPGoals<140and<90mmHg
Patientswithmostconditions<130and<80mmHgDiabetesMellitusCKDAlbuminuria>300mg/24hror>200mg/gurinarycreatinineeGFR<60ml/min/1.73m2SerumcreatininelevelsaloneoverestimatekidneyfunctionAssessandaddressothercardiovascularriskfactorsChobanianAVetal.JAMA.2003;289:2560-2572.JNC7RecommendedBPGoals<14066JNC7:ManagementofHypertensionbyBPClassificationJNC7:ManagementofHypertens67CommonProviderConcernswithGuidelineGoals
NonAcceptanceofBPgoalsResistancetoacceptSBPthresholdsNottreatingunlessSBP>160mmHgConcernsofincreasedcardiovascularriskwithexcessiveloweringofDBP(J-Curve)BelievethatmoretimeisneededtoreachgoalVALUE,
LANCET,2004:363:2022-2031CommonProviderConcernswith68Ruleof3
“MDBP”3
Months3
Drugs3
Behaviors
(activity-diet-alcoholandtobaccocontrol)3
Partners
(Patient–Family–Provider)Ruleof3
“MDBP”3Months69
ItMightTake3MonthsGettingBPtogoalin3monthsRequiresmultiplevisitsGettingtoGoalvisitschedule:MonthlyuntilgoalisreachedIncreasevisitfrequencyifStage2Increasevisitfrequencywithcomorbidconditions
Atgoal–followupvisitscheduleEvery3-6monthsdependingoncomorbiditiesCheckK+andCreatinine1-2x/year
ItMightTake3MonthsGetting70
DrugTherapyStepApproach:StartwithdiureticifnocontraindicationsAddACEICalciumChannelBlocker(CCB)Betablockers–butcautionMostpatientsrequire
multipledrugstoachievecontrol(average=3.5drugs)Usemultipledrugsif:BP20/10mmHgabovegoal(Stage22drugs)StandingBPabovegoalinpatientsoverage65orDMNotatgoalafter3months
DrugTherapyStepApproach:71MultipleAntihypertensiveAgentsAreNeededtoAchieveTargetBloodPressureMultipleAntihypertensiveAgen72DrugTreatment:DiureticsIfnocompellingindications(CHF,diabetes,CKD)Chlorthalidone(orotherthiazides)firstThenACEIorARBRememberBetaBlockersARENOTforprimarypreventionandareinferiortodiureticsasmonotherapyVigilantlypreventhypokalemiaSpironolactone/HCTZisagreatcombination!BringpatientsbackinoneweektocheckfordiureticinducedhypokalemiaWatchforhyponatremiaDrugTreatment:DiureticsIfno73DrugTreatment:ACEinhibitorsCheckElectrolytes,BUN,andCreatininepriortostartingRecheckK+andCreatinine1weekafterinitiationoftherapyGenericavailableBIDDosing:enalapril(5mgbid-20mgbid)captopril(12.5mgbid-50mgbid)DailyDosinglisinopril(5-40mgdaily)Sideeffects:Cough-switchtoARBifaffordableHyperkalemiaandacuterenalfailureAngioedemaDrugTreatment:ACEinhibitors74WhatHaveWeLearned?
TreatmentTreatmentoftheveryelderlydecreases strokeandCADbutdoesnotprolongsurvival(Lancet1999:353:793)Bestdrugsinrankorder:ChlorthalidoneACEinhibitorHCTZ(Hypertension2004;44:800)CCB
WhatHaveWeLearned?
Treatme75WhatHaveWeLearned?
TreatmentACEIandARBdecreasenewonsetofdiabetesby25%comparedtobetablockers(LIFE);23%comparedtoCCBs(VALUEtrial)NewonsetofdiabeteswhileundergoingtreatmentforhypertensionconfersthesameexcessCVriskaspreexistingdiabetes(Hypertension(2004)43p.963)WhatHaveWeLearned?
Treatme76WhatHaveWeLearned?
TreatmentMonotherapywithatenololisNOTasefficaciousasotherantihypertensivesfordecreasingCVriskdespiteequivalentBPcontrol(Lancet:2004:364:1684)BetablockersareinferiortodiureticsforbloodpressurecontrolandCVriskprotection(stroke,CHF)inolderpatients(MRCtrial,1990;JAMA
1998;279:1903-1907;INVEST:JAMA290:2805-2816;ASCOTTrial)WhatHaveWeLearned?
Treatme77CombinationTreatmentsLogical/additivecombinationsDiuretic+ACEIorARBDiuretic+BetaBlockerorsympatholyticsCCB+ACEIorARBDiuretic+BetaBlocker+vasodilatorDiuretic+CCBCombinationTreatmentsLogical78CombinationTreatmentsCombinationswithNOadditiveeffectBetaBlocker+ACEIVasodilators+CCBCombinationwithadditivesideeffectsBetaBlocker+clonidineorguanfacineBetaBlocker+verapamilordiltiazemClonidine/guanfacine+verapamilordiltiazemCombinationTreatmentsCombinat79Whenadding
Indifficulttocontrolpatients
ItTakes3DRUGS!ChoosealogicalADDITIVEcombinations:Diuretic+ACEI+CCBDiuretic+BBlocker+vasodilatorDiuretic+clonidine+vasodilatorWhenadding
80SpecialPopulationsDiabetesACEIorARBDiureticsareimportantadjuncttherapyBScontrolassociatedwithBPcontrolCKDACEIorARBareimportanttopreserverenalfunctionIfeGFR<50starttorsemideorfurosemidebidPostMIBetablockersACEIorARBCheckK+andCreatininepriortoinitiatingand1weekafterinitiatingACESpecialPopulationsDiabetes81
ItMightTake3MonthsButifnotatgoalby6monthsconsider:PatientreasonsfornonadherenceSleepApneaAlcoholoveruseDiabetesChronicKidneyDiseaseSecondarycausesConsultwithorrefertoHypertensionSpecialist
VALUE,LANCET,2004:363:2022-2031
ItMightTake3MonthsButif82SleepApneaUpto60%maleswithresistanthypertension(alsocommoninpostmenopausalfemales)Suspectdiagnosis-screenandreferPathophysiologyofhypertensionlikelySNSactivationSleepApneaUpto60%maleswit83
Lifestyle:ItTakes3BEHAVIORSExerciseDietControloftobaccoandalcohol
Lifestyle:ItTakes3BEHAVIO84Lifestyle:Exercise4-9mmHgSBPreduction30-45minutes/day/5-7days/weekAerobicactivity(e.g.briskwalking)WriteaprescriptionFavoritePatientSig40minutesofwalking5X/wk BPMD3333Lifestyle:Exercise4-9mmHgSBP85Lifestyle:DietWeightControl
5-20mmHgSBPreduction/10kgLowSodium(<2.4g)
2-8mmHgSBPreductionDASH8-14mmHgSBPreductionLifestyle:DietWeightControl86ControlofTobaccoandAlcoholSmokingCessationWriteprescriptionAlcoholModeration<2alcoholicdrinks/day–men<1alcoholicdrink/day–women2-4mmHgreductioninSBPAccessforothersubstancesControlofTobaccoandAlcohol87Partners:Ittakes3PartnersPatientFamilyProviderProvider/Pa
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年度教育設(shè)備租賃及教學(xué)支持服務(wù)合同
- 2025年度綠色建筑項(xiàng)目監(jiān)理委托合同范本
- 2025年度綠色建筑設(shè)計(jì)咨詢與施工監(jiān)督合同
- 2025年度旅游行業(yè)專用購物卡銷售與營銷推廣合同模板
- 2025年度跨境電商知識(shí)產(chǎn)權(quán)保護(hù)代理服務(wù)合同
- 2025年度智能交通系統(tǒng)建設(shè)與運(yùn)營合同-@-3
- 2025年度建筑工程工人勞動(dòng)爭議調(diào)解服務(wù)合同
- 2025年度股權(quán)部分轉(zhuǎn)讓與公司員工持股平臺(tái)設(shè)立合同范本
- 2025年度智能化公文合同格式合同模板及示范范文匯編
- 2025年中國丁二酸行業(yè)市場動(dòng)態(tài)分析、發(fā)展方向及投資前景分析報(bào)告
- 反走私課件完整版本
- 通信工程制圖(微課版)課程標(biāo)準(zhǔn)
- 四年級下冊數(shù)學(xué)知識(shí)點(diǎn)總結(jié)
- 第三屆全國石油工程設(shè)計(jì)大賽作品(油藏工程設(shè)計(jì)單項(xiàng))
- (人衛(wèi)版第九版?zhèn)魅静W(xué)總論(一))課件
- 壓力性損傷護(hù)理質(zhì)控細(xì)則及集束化管理措施
- 《批判性思維原理和方法》全套教學(xué)課件
- 產(chǎn)后康復(fù)-腹直肌分離
- 丙烯-危險(xiǎn)化學(xué)品安全周知卡
- 2024-2030年中國免疫檢查點(diǎn)抑制劑行業(yè)市場研究分析及投資機(jī)會(huì)預(yù)測報(bào)告
- 《太常引·建康中秋夜為呂叔潛賦》示范課教學(xué)設(shè)計(jì)(部編人教版九年級語文下冊)
評論
0/150
提交評論